-
CRISPR Therapeutics NASDAQ:CRSP CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.
Location: Baarerstrasse 14, Zug, 6300, Switzerland | Website: www.crisprtx.com | Industry: Biological Product (except Diagnostic) Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
1.835B
Cash
1.936B
Avg Qtr Burn
-47.2M
Short % of Float
22.76%
Insider Ownership
1.71%
Institutional Own.
84.67%
Qtr Updated
09/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Approved Quarterly sales | ||
Approved Quarterly sales | ||
CTX110 (CD19) Details CD19+ malignancies, B-cell malignancies, Cancer, Blood cancer | Phase 2 Data readout | |
CTX211 (formerly VCTX211) Details Type 1 diabetes | Phase 1/2 Data readout | |
Phase 1/2 Update | ||
Phase 1/2 Update | ||
CTX112 Details Systemic lupus erythematosus | Phase 1 Data readout | |
VCTX210 Details Type 1 diabetes | Phase 1 Data readout | |
CTX130 (CD70) Details Blood cancer, Cancer, T-cell lymphoma | Phase 1 Update | |
CTX131 (CD70) Details Cancer, Solid tumor/s | Phase 1 Update | |
CTX112 Details CD19+ malignancies, Blood cancer, Cancer, B-cell malignancies | Phase 1 Update | |
CTX310 (ANGPTL3) Details Atherosclerotic cardiovascular disease | Phase 1 Update | |
CTX320 Lp(a) Details Atherosclerotic cardiovascular disease | Phase 1 Update | |
CTX120 (BCMA) Details Multiple myeloma, Blood cancer, Cancer | Failed Discontinued |